SRPT:NSD-Sarepta Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 71.10

Change

0.00 (0.00)%

Market Cap

USD 6.19B

Volume

1.22M

Avg Analyst Target

USD 116.85 (+64.34%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Sarepta Therapeutics Inc (SRPT) Stock Analysis:
Based on the Sarepta Therapeutics Inc stock forecasts from 12 analysts, the average analyst target price for Sarepta Therapeutics Inc is USD 116.85 over the next 12 months. Sarepta Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sarepta Therapeutics Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Sarepta Therapeutics Inc’s stock price was USD 71.10. Sarepta Therapeutics Inc’s stock price has changed by -5.05% over the past week, -16.80% over the past month and -21.28% over the last year.

About

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to t ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD59.51B 28.07 15.97
BNTX BioNTech SE

N/A

USD47.53B 6.14 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

N/A

USD25.07B 55.02 44.86
BGNE BeiGene Ltd

N/A

USD24.70B N/A N/A
GMAB Genmab A/S

N/A

USD23.58B 53.39 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

N/A

USD17.76B N/A N/A

ETFs Containing SRPT

Symbol Name Weight Mer Price(Change) Market Cap
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

N/A

USD0.25B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

USD0.33B
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

+14.95 (+1.69%)

USD0.03B
NIFE Direxion Fallen Knives ET.. 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.04% 15% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.04% 15% F 8% F
Trailing 12 Months  
Capital Gain -21.28% 76% C 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.28% 76% C 35% F
Trailing 5 Years  
Capital Gain 97.61% 75% C 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.61% 75% C 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 43.91% 73% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.91% 73% C 83% B
Risk Return Profile  
Volatility (Standard Deviation) 89.20% 32% F 18% F
Risk Adjusted Return 49.23% 79% C+ 69% D+
Market Capitalization 6.19B 96% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.85 6% F 7% F
Price / Cash Flow Ratio 57.61 2% F 7% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -71.41% 40% F 22% F
Return on Invested Capital -34.74% 63% D 22% F
Return on Assets -11.82% 82% B- 27% F
Debt to Equity Ratio 130.29% 10% F 16% F
Technical Ratios  
Short Ratio 5.69 28% F 17% F
Short Percent 6.08% 35% F 27% F
Beta 1.25 50% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector